Subjects assigned to receive empagliflozin will be dosed at 10 mg per day for the duration of the study.~Approximately 30 subjects will be enrolled per treatment arm.
A randomized, multi-center study evaluating MET409 (50 mg) alone or in combination with empagliflozin (10 mg) for 12 weeks. Assignment to MET409 will be double-blind and placebo-controlled. Empagliflozin will be incorporated into two of the treatment arms in an open-label manner.